Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer ResearchHidalgo, M., Amant, F., Biankin, A. V., Budinska, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Maelandsmo, G. M., Roman-Roman, S., Seoane, J., Trusolino, L., Villanueva, A. & EurOPDX Consortium, Sep-2014, In : Cancer discovery. 4, 9, p. 998-1013 16 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models.
Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field. (C) 2014 AACR.
|Number of pages||16|
|Publication status||Published - Sep-2014|
- HUMAN PANCREATIC-CANCER, TUMOR XENOGRAFTS, NUDE-MICE, COLORECTAL-CANCER, STEM-CELLS, IN-VIVO, PERSONALIZED CHEMOTHERAPY, THERAPEUTIC RESPONSE, IMMUNODEFICIENT MICE, DRUG DEVELOPMENT